<?xml version="1.0" encoding="UTF-8"?>
<jcr:root xmlns:sling="http://sling.apache.org/jcr/sling/1.0" xmlns:cq="http://www.day.com/jcr/cq/1.0" xmlns:jcr="http://www.jcp.org/jcr/1.0" xmlns:mix="http://www.jcp.org/jcr/mix/1.0" xmlns:nt="http://www.jcp.org/jcr/nt/1.0"
    jcr:primaryType="cq:Page">
    <jcr:content
        cq:contextHubPath="/etc/cloudsettings/default/contexthub"
        cq:contextHubSegmentsPath="/etc/segmentation/contexthub"
        cq:lastModified="{Date}2020-08-14T20:03:37.643+05:30"
        cq:lastModifiedBy="admin"
        cq:lastReplicated="{Date}2020-08-13T20:33:09.077+05:30"
        cq:lastReplicatedBy="admin"
        cq:lastReplicationAction="Activate"
        cq:template="/conf/sanjeevni/settings/wcm/templates/sanjeevni-base-page-template"
        jcr:isCheckedOut="{Boolean}true"
        jcr:mixinTypes="[mix:versionable]"
        jcr:primaryType="cq:PageContent"
        jcr:title="Viral vector vaccine"
        jcr:uuid="1f294ce5-065b-4a7f-9e3a-a83620d455ad"
        sling:resourceType="sanjeevni/components/structure/page"
        pageTitle="Viral Vector"
        socialMedia="[facebook]">
        <root
            jcr:primaryType="nt:unstructured"
            sling:resourceType="wcm/foundation/components/responsivegrid">
            <responsivegrid
                jcr:lastModifiedBy="admin"
                jcr:primaryType="nt:unstructured"
                sling:resourceType="wcm/foundation/components/responsivegrid">
                <text_1863451963_copy
                    jcr:created="{Date}2020-08-05T18:05:12.533+05:30"
                    jcr:createdBy="admin"
                    jcr:lastModified="{Date}2020-08-13T16:11:20.565+05:30"
                    jcr:lastModifiedBy="admin"
                    jcr:primaryType="nt:unstructured"
                    sling:resourceType="sanjeevni/components/content/text"
                    text="&lt;table cellpadding=&quot;1&quot; cellspacing=&quot;0&quot; border=&quot;1&quot;>&#xd;&#xa;&lt;tbody>&lt;tr>&lt;th valign=&quot;middle&quot; style=&quot;text-align: center;&quot;>&lt;b>Sl.No&lt;/b>&lt;/th>&#xd;&#xa;&lt;th scope=&quot;col&quot; valign=&quot;middle&quot; style=&quot;text-align: center;&quot;>&lt;b>&amp;nbsp;Company and Partnership&lt;/b>&lt;/th>&#xd;&#xa;&lt;th>&lt;b>Origin&lt;/b>&lt;/th>&#xd;&#xa;&lt;th scope=&quot;col&quot; valign=&quot;middle&quot; style=&quot;text-align: center;&quot;>&lt;b>Pre-Clinical&lt;/b>&lt;/th>&#xd;&#xa;&lt;th scope=&quot;col&quot; valign=&quot;middle&quot; style=&quot;text-align: center;&quot;>&amp;nbsp; &lt;b>Phase-I&lt;/b>&amp;nbsp; &amp;nbsp;&lt;/th>&#xd;&#xa;&lt;th scope=&quot;col&quot;>&amp;nbsp; &amp;nbsp; &lt;b>Phase-II&lt;/b>&amp;nbsp; &amp;nbsp;&lt;/th>&#xd;&#xa;&lt;th scope=&quot;col&quot; valign=&quot;middle&quot; style=&quot;text-align: center;&quot;>&amp;nbsp; &amp;nbsp; &lt;b>Phase-III&lt;/b>&amp;nbsp; &amp;nbsp;&lt;/th>&#xd;&#xa;&lt;/tr>&lt;tr>&lt;td valign=&quot;middle&quot; style=&quot;text-align: center;&quot;>1&lt;/td>&#xd;&#xa;&lt;td>&lt;a href=&quot;/content/sanjeevni/vaccine-progress/viral-vector-vaccine.html#1&quot; target=&quot;_self&quot;>AstraZeneca and University of Oxford&lt;/a>&lt;/td>&#xd;&#xa;&lt;td>UK&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp;&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp;&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp; &amp;nbsp; &amp;nbsp; X&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp;X&lt;/td>&#xd;&#xa;&lt;/tr>&lt;tr>&lt;td valign=&quot;middle&quot; style=&quot;text-align: center;&quot;>2&lt;/td>&#xd;&#xa;&lt;td>&lt;a href=&quot;/content/sanjeevni/vaccine-progress/viral-vector-vaccine.html#2&quot; target=&quot;_self&quot;>CanSino Biologics and Academy of Military Sciences&lt;/a>&lt;/td>&#xd;&#xa;&lt;td>United Kingdom&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp;&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp;&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp; &amp;nbsp; &amp;nbsp; X&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp;&lt;/td>&#xd;&#xa;&lt;/tr>&lt;tr>&lt;td valign=&quot;middle&quot; style=&quot;text-align: center;&quot;>3&lt;/td>&#xd;&#xa;&lt;td>&lt;a href=&quot;/content/sanjeevni/vaccine-progress/viral-vector-vaccine.html#3&quot; target=&quot;_self&quot;>Johnson &amp;amp; Johnson and Beth Israel Deaconess Medical Center&lt;/a>&lt;/td>&#xd;&#xa;&lt;td>United States of America&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp;&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp; &amp;nbsp; &amp;nbsp;X&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp; &amp;nbsp; &amp;nbsp; X&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp;&lt;/td>&#xd;&#xa;&lt;/tr>&lt;tr>&lt;td valign=&quot;middle&quot; style=&quot;text-align: center;&quot;>4&lt;/td>&#xd;&#xa;&lt;td>&lt;a href=&quot;/content/sanjeevni/vaccine-progress/viral-vector-vaccine.html#4&quot; target=&quot;_self&quot;>Gamaleya Research Institute&lt;/a>&lt;/td>&#xd;&#xa;&lt;td>Russia&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp;&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp; &amp;nbsp; &amp;nbsp;X&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp;&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp;&lt;/td>&#xd;&#xa;&lt;/tr>&lt;tr>&lt;td valign=&quot;middle&quot; style=&quot;text-align: center;&quot;>5&lt;/td>&#xd;&#xa;&lt;td>&lt;a href=&quot;/content/sanjeevni/vaccine-progress/viral-vector-vaccine.html#5&quot; target=&quot;_self&quot;>Massachusetts Eye and Ear Hospital and Novartis&amp;nbsp;&lt;/a>&lt;/td>&#xd;&#xa;&lt;td>Switzerland&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp;X&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp;&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp;&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp;&lt;/td>&#xd;&#xa;&lt;/tr>&lt;tr>&lt;td valign=&quot;middle&quot; style=&quot;text-align: center;&quot;>6&lt;/td>&#xd;&#xa;&lt;td>&lt;a href=&quot;/content/sanjeevni/vaccine-progress/viral-vector-vaccine.html#6&quot; target=&quot;_self&quot;>Merck and IAVI&amp;nbsp;&lt;/a>&lt;/td>&#xd;&#xa;&lt;td>United States of America&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp;X&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp;&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp;&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp;&lt;/td>&#xd;&#xa;&lt;/tr>&lt;tr>&lt;td valign=&quot;middle&quot; style=&quot;text-align: center;&quot;>7&lt;/td>&#xd;&#xa;&lt;td>&lt;a href=&quot;/content/sanjeevni/vaccine-progress/viral-vector-vaccine.html#7&quot; target=&quot;_self&quot;>Merck and Themis Bioscience&lt;/a>&lt;/td>&#xd;&#xa;&lt;td>United States of America&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp;X&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp;&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp;&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp;&lt;/td>&#xd;&#xa;&lt;/tr>&lt;tr>&lt;td valign=&quot;middle&quot; style=&quot;text-align: center;&quot;>8&lt;/td>&#xd;&#xa;&lt;td>&lt;a href=&quot;/content/sanjeevni/vaccine-progress/viral-vector-vaccine.html#8&quot; target=&quot;_self&quot;>Vaxart&lt;/a>&lt;/td>&#xd;&#xa;&lt;td>United States of America&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp;X&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp;&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp;&lt;/td>&#xd;&#xa;&lt;td>&amp;nbsp;&lt;/td>&#xd;&#xa;&lt;/tr>&lt;/tbody>&lt;/table>&#xd;&#xa;"
                    textIsRich="true">
                    <cq:responsive jcr:primaryType="nt:unstructured">
                        <default
                            jcr:primaryType="nt:unstructured"
                            offset="2"
                            width="8"/>
                    </cq:responsive>
                </text_1863451963_copy>
                <viewchilds
                    jcr:created="{Date}2020-07-13T17:02:12.540+05:30"
                    jcr:createdBy="admin"
                    jcr:lastModified="{Date}2020-08-14T20:03:37.631+05:30"
                    jcr:lastModifiedBy="admin"
                    jcr:primaryType="nt:unstructured"
                    sling:resourceType="sanjeevni/components/content/viewChilds">
                    <products jcr:primaryType="nt:unstructured">
                        <item0
                            jcr:primaryType="nt:unstructured"
                            desc="A vaccine in development by the British-Swedish company AstraZeneca and the University of Oxford is based on a chimpanzee adenovirus called ChAdOx1. A study on monkeys found that the vaccine provided them protection. Their Phase I/II trial, reported on July 20 in the journal Lancet, found that the vaccine was safe, causing no severe side effects. It raised antibodies against the coronavirus as well as other immune defenses. The vaccine is now in a Phase II/III trial in England, as well as Phase III trials in Brazil and South Africa. The project may deliver emergency vaccines by October. AstraZeneca has said their total manufacturing capacity for the vaccine, if approved, stands at two billion doses."
                            iD="1"
                            linkPage="#"
                            pathbr="/content/dam/sanjeevni/vaccine-progress/astrazeneca-800.png"
                            product="AstraZeneca and University of Oxford"/>
                        <item1
                            jcr:primaryType="nt:unstructured"
                            desc="The Chinese company CanSino Biologics developed a vaccine based on an adenovirus called Ad5, in partnership with the Institute of Biology at the country’s Academy of Military Medical Sciences. In May, they published promising results from a Phase I safety trial, and in July they reported that their Phase II trials demonstrated the vaccine produced a strong immune response. In an unprecedented move, the Chinese military approved the vaccine on June 25 for a year as a “specially needed drug.” CanSino would not say whether vaccination would be mandatory or optional for soldiers."
                            iD="2"
                            linkPage="#"
                            pathbr="/content/dam/sanjeevni/vaccine-progress/cansino-800.png"
                            product="CanSino Biologics and Academy of Military Sciences"/>
                        <item2
                            jcr:primaryType="nt:unstructured"
                            desc="A decade ago, researchers at Beth Israel Deaconess Medical Center in Boston developed a method for making vaccines out of a virus called Adenovirus 26, or Ad26 for short. Johnson &amp; Johnson developed vaccines for Ebola and other diseases with Ad26 and have now made one for the coronavirus. In March they received $456 million from the United States government to support their move towards production. The vaccine has provided protection in experiments on monkeys. Johnson &amp; Johnson launched Phase I/II trials in July and is planning for Phase III trials in September. If their vaccine is approved, they have hopes of making a billion doses in 2021."
                            iD="3"
                            linkPage="#"
                            pathbr="/content/dam/sanjeevni/vaccine-progress/jnj-800.png"
                            product="Johnson &amp; Johnson and Beth Israel Deaconess Medical Center"/>
                        <item3
                            jcr:primaryType="nt:unstructured"
                            desc="The Gamaleya Research Institute, part of Russia’s Ministry of Health, launched a Phase I trial in June of a vaccine they call Gam-Covid-Vac Lyo. It is a combination of two adenoviruses, Ad5 and Ad26, both engineered with a coronavirus gene. In July, the chair of the upper house of Russia’s Parliament announced the country may start vaccine production by the end of the year."
                            iD="4"
                            linkPage="#"
                            pathbr="/content/dam/sanjeevni/vaccine-progress/russiahealth-800.png"
                            product="Gamaleya Research Institute"/>
                        <item4
                            jcr:primaryType="nt:unstructured"
                            desc="The Swiss company Novartis will manufacture a vaccine based on a gene therapy treatment developed by the Massachusetts Eye and Ear Hospital. A virus called an adeno-associated virus delivers coronavirus gene fragments into cells. Phase I trials are set to begin in late 2020."
                            iD="5"
                            linkPage="#"
                            pathbr="/content/dam/sanjeevni/vaccine-progress/mee-800.png"
                            product="Massachusetts Eye and Ear Hospital and Novartis "/>
                        <item5
                            jcr:primaryType="nt:unstructured"
                            desc="The American company Merck announced in May it would develop a vaccine from vesicular stomatitis viruses, the same approach it successfully used to produce the only approved vaccine for Ebola. The company is partnering with IAVI and has received $38 million in support from the United States government."
                            iD="6"
                            linkPage="#"
                            pathbr="/content/dam/sanjeevni/vaccine-progress/merck-800.png"
                            product="Merck  and IAVI "/>
                        <item6
                            jcr:primaryType="nt:unstructured"
                            desc="Merck is also working with Themis Bioscience, an Austrian firm it is acquiring, to develop a second vaccine, which will use the measles virus to carry genetic material into patients’ cells."
                            iD="7"
                            linkPage="#"
                            pathbr="/content/dam/sanjeevni/vaccine-progress/merck-800.png"
                            product="Merck and Themis Bioscience"/>
                        <item7
                            jcr:primaryType="nt:unstructured"
                            desc="Vaxart’s vaccine is an oral tablet containing an adenovirus that delivers corona virus genes. They are preparing for Phase I trials this summer."
                            iD="8"
                            linkPage="#"
                            pathbr="/content/dam/sanjeevni/vaccine-progress/vaxart-800.png"
                            product="Vaxart"/>
                    </products>
                </viewchilds>
            </responsivegrid>
        </root>
    </jcr:content>
</jcr:root>
